Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

IMMUNOCORE HOLDINGS PLC

(IMCR)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Immunocore : Tebentafusp Accepted for Marketing Authorization Review by UK Regulator

09/08/2021 | 07:56am EDT


© MT Newswires 2021
All news about IMMUNOCORE HOLDINGS PLC
10/18IMMUNOCORE : to Collaborate With Medison Pharma to Expand Reach of Metastatic Uveal Melano..
MT
10/18IMMUNOCORE : and Medison Pharma Partner for Future Commercialization of Tebentafusp in Can..
GL
10/18Immunocore and Medison Pharma Partner for Future Commercialization of Tebentafusp in Ca..
GL
09/22IMMUNOCORE : announces publication of phase 3 data comparing tebentafusp with investigator..
AQ
09/22Immunocore Announces Publication of Phase 3 Data Comparing tebentafusp with Investigato..
CI
09/21IMMUNOCORE : Dr. Carolin Barth Joins MiroBio as CEO to Lead Precision Immunology Company F..
AQ
09/20IMMUNOCORE : Reports Data From Phase 2 Trial of Tebentafusp
MT
09/20Immunocore presents data at the European Society for Medical Oncology (ESMO) Congress 2..
GL
09/20Immunocore Presents Data At the European Society for Medical Oncology Congress 2021 Dem..
CI
09/13IMMUNOCORE : Announces Upcoming Presentations at the European Society for Medical Oncology..
AQ
More news
Analyst Recommendations on IMMUNOCORE HOLDINGS PLC
More recommendations
Financials
Sales 2021 24,3 M 33,6 M 33,6 M
Net income 2021 -137 M -189 M -189 M
Net cash 2021 163 M 225 M 225 M
P/E ratio 2021 -9,09x
Yield 2021 -
Capitalization 1 263 M 1 745 M 1 743 M
EV / Sales 2021 45,2x
EV / Sales 2022 36,9x
Nbr of Employees 291
Free-Float 73,4%
Chart IMMUNOCORE HOLDINGS PLC
Duration : Period :
Immunocore Holdings plc Technical Analysis Chart | IMCR | US45258D1054 | MarketScreener
Technical analysis trends IMMUNOCORE HOLDINGS PLC
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 2 883,50 GBX
Average target price 3 840,58 GBX
Spread / Average Target 33,2%
EPS Revisions
Managers and Directors
Bahija Jallal Chief Executive Officer & Director
Brian R. DiDonato Chief Financial Officer & Head-Strategy
David Berman Head-Research & Development
Roy Steven Herbst Non-Executive Director
John Irving Bell Non-Executive Director
Sector and Competitors
1st jan.Capi. (M$)
IMMUNOCORE HOLDINGS PLC0.00%1 745
MODERNA, INC.218.76%134 418
LONZA GROUP AG29.18%59 339
IQVIA HOLDINGS INC.40.38%48 194
SEAGEN INC.-0.17%31 811
CELLTRION, INC.-39.00%25 446